Good Health Can’t Wait.

Good Health Can’t Wait.
Dr. Reddy’s Laboratories Limited
NOTES TO FINANCIAL STATEMENTS
(All amounts in Indian Rupees millions, except share data and where otherwise stated)
2.27: RELATED PARTY DISCLOSURES (CONTINUED)
d. Particulars of related party transactions
The following is a summary of significant related party transactions:
PARTICULARS
FOR THE YEAR ENDED
31 MARCH 2015
FOR THE YEAR ENDED
31 MARCH 2014
i. Revenues from:
Subsidiaries including step down subsidiaries:
Dr.Reddy’s Laboratories Inc. 38,439 37,695
OOO Dr.Reddy’s Laboratories Limited 10,135 12,062
Dr.Reddy’s Laboratories SA 4,883 5,289
Others 8,812 6,365
Total 62,269 61,411
Other related parties:
Ecologic Chemicals Limited - 49
Total - 49
ii. Sale of assets to Ecologic Chemicals Limited - 14
iii. Interest income from subsidiaries including step down subsidiaries:
Industrias Quimicas Falcon de Mexico S.A. de C.V. 187 74
DRL Impex Limited 35 43
Dr. Reddy’s Laboratories (Australia) Pty. Limited - 15
Total 222 132
iv. Service income from subsidiaries including step down subsidiaries:
Dr.Reddy’s Laboratories Inc. 56 21
Dr.Reddy’s Laboratories SA 8 6
Chirotech Technology Limited 1 14
Aurigene Discovery Technologies Limited - 1
Dr. Reddy’s Laboratories (EU) Limited 9 -
Total 74 42
v. Licence fees from subsidiaries including step down subsidiaries:
betapharm Arzneimittel GmbH 64 785
Dr.Reddy’s Laboratories SA - 313
Dr.Reddy’s Laboratories Inc. 39 38
Total 103 1,136
vi. Commission on guarantee from subsidiaries including step down subsidiaries:
Dr.Reddy’s Laboratories SA 132 145
betapharm Arzneimittel GmbH - 11
Lacock Holdings Limited - 20
Total 132 176
vii. Rent from Aurigene Discovery Technologies Limited 14 14
viii. Dividend income from Aurigene Discovery Technologies Limited 79 12
ix.
Reimbursement of operating and other expenses by subsidiaries and step down
subsidiaries:
Aurigene Discovery Technologies Limited 35 40
Dr.Reddy’s Laboratories SA - 2
Others 2 50
Total 37 92
142